0000899243-20-009846.txt : 20200401
0000899243-20-009846.hdr.sgml : 20200401
20200401170802
ACCESSION NUMBER: 0000899243-20-009846
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200330
FILED AS OF DATE: 20200401
DATE AS OF CHANGE: 20200401
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dananberg Jamie
CENTRAL INDEX KEY: 0001734424
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38470
FILM NUMBER: 20766174
MAIL ADDRESS:
STREET 1: 3280 BAYSHORE BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Unity Biotechnology, Inc.
CENTRAL INDEX KEY: 0001463361
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 264726035
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3280 BAYSHORE BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: (415) 328-5504
MAIL ADDRESS:
STREET 1: 3280 BAYSHORE BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: Cenexys, Inc.
DATE OF NAME CHANGE: 20130703
FORMER COMPANY:
FORMER CONFORMED NAME: Forge Inc
DATE OF NAME CHANGE: 20090504
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-30
0
0001463361
Unity Biotechnology, Inc.
UBX
0001734424
Dananberg Jamie
C/O UNITY BIOTECHNOLOGY, INC.
285 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Medical Officer
Common Stock, $0.0001 par value
2020-03-30
4
A
0
24255
0.00
A
454702
D
Stock Option (Right to Buy)
5.95
2020-03-30
4
A
0
98490
0.00
A
2030-03-29
Common Stock
98490
98490
D
Represents Restricted Stock Units ("RSUs") which vest in equal annual installments over a three year period measured from March 30, 2020. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
Includes RSUs which vest over time measured from the grant date.
Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on March 30, 2020 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
/s/ Tamara L. Tompkins, Attorney-in-Fact for Jamie Dananberg
2020-04-01